Abstract 15618: Incremental Cardiovascular Benefit of GLP-1 Therapy in Patients with HFrEF and Type 2 Diabetes on Quadruple GDMT
Background: Patients with heart failure with reduced ejection fraction (HFrEF) and type 2 diabetes mellitus (T2DM) remain at high residual cardiovascular risk despite guideline-directed medical therapy (GDMT). Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have demonstrated cardiometabolic benefits, but their...